Nuvalent (NUVL) Non-cash Items (2021 - 2026)
Nuvalent (NUVL) reported Non-cash Items of $465.5 million for Q1 2026, up 9665.04% on a YoY basis from $4.8 million in Q1 2025, and down 2.28% quarter-over-quarter from $476.4 million in Q4 2025.
Nuvalent (NUVL) Non-cash Items (2021 - 2026) Analysis & Trends
Nuvalent has reported Non-cash Items for 6 years, with the latest figure at $465.5 million in Q1 2026.
- For the quarter ending Q1 2026, Non-cash Items rose 9665.04% year-over-year to $465.5 million; the trailing twelve-month figure through Mar 2026 stood at $465.5 million (up 9665.04% YoY), and the FY2025 full-year result was $4.7 million, down 98.82% from the prior year.
- Non-cash Items for Q1 2026 stood at $465.5 million, down from $476.4 million in the prior quarter.
- The five-year high for Non-cash Items was $476.4 million in Q4 2025, with the low at $437972.0 in Q1 2024.
- Historically, Non-cash Items has averaged $247.7 million across 5 years, with a median of $360.9 million in 2025.
- Annual changes were most pronounced in 2025 — Non-cash Items retreated 16.25% — and 2026, when it jumped 9665.04%.
- Nuvalent's Non-cash Items stood at $128.3 million in 2022, then jumped by 250.32% to $449.4 million in 2023, then retreated by 11.35% to $398.4 million in 2024, then gained by 19.56% to $476.4 million in 2025, then dropped by 2.28% to $465.5 million in 2026.
- The last three Non-cash Items figures came in at $465.5 million (Q1 2026), $476.4 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 465.51 Mn |
| Mar 31, 2026 | 465.51 Mn |
| Dec 31, 2025 | 476.36 Mn |
| Dec 31, 2025 | 476.36 Mn |
| Sep 30, 2025 | 5.26 Mn |
| Sep 30, 2025 | 5.26 Mn |
| Jun 30, 2025 | 360.93 Mn |
| Jun 30, 2025 | 360.93 Mn |
| Mar 31, 2025 | 4.77 Mn |
| Mar 31, 2025 | 4.77 Mn |
| Dec 31, 2024 | 398.41 Mn |
| Dec 31, 2024 | 398.41 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 430.98 Mn |
| Jun 30, 2024 | 430.98 Mn |
| Mar 31, 2024 | 437,972.00 |
| Mar 31, 2024 | 437,972.00 |
| Dec 31, 2023 | 449.40 Mn |
| Dec 31, 2023 | 449.40 Mn |